Overall survival (OS) results from the phase III TROPiCS-02 study of sacituzumab govitecan (SG) vs treatment of physician's choice (TPC) in patients (pts) with HR+/HER2-metastatic breast cancer (mBC)

被引：42

作者：

Rugo, H. S. ^{[1
]}

Bardia, A. ^{[2
]}

Marme, F. ^{[3
]}

Cortes, J. ^{[4
]}

Schmid, P. ^{[5
,6
,7
]}

Loirat, D. ^{[8
,9
]}

Tredan, O. ^{[10
]}

Ciruelos, E. M. ^{[11
]}

Dalenc, F. ^{[12
]}

Gomez Pardo, P. ^{[13
]}

Jhaveri, K. ^{[14
]}

Delaney, R. J. ^{[15
]}

Valdez, T. ^{[16
]}

Wang, H. ^{[17
]}

Verret, W. ^{[15
]}

Tolaney, S. M. ^{[18
]}

机构：

[1] Univ Calif San Francisco, Dept Med, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA

[2] Harvard Med Sch, Massachusetts Gen Hosp, Med Oncol, Canc Ctr, Boston, MA USA

[3] Heidelberg Univ, Med Fac Mannheim, Gynecol Oncol Dept, Dept Obstet & Gynaecol, Heidelberg, Germany

[4] Queen Mary Univ London, Barts Canc Inst, Ctr Expt Canc Med, London, England

[5] Quirosalud Grp, Med Oncol Dept, Int Breast Canc Ctr IBCC, Pangaea Oncol, Madrid, Spain

[6] Quirosalud Grp, Med Oncol Dept, Int Breast Canc Ctr IBCC, Pangaea Oncol, Barcelona, Spain

[7] Univ Europea Madrid, Fac Biomed & Hlth Sci, Dept Med, Madrid, Spain

[8] Inst Curie, Med Oncol Dept, Paris, France

[9] Inst Curie, D3i, Paris, France

[10] Ctr Leon Berard, Med Oncol Dept, Lyon, France

[11] Hosp Univ 12 Octubre, Med Oncol, Madrid, Spain

[12] Inst Claudius Regaud, Med Oncol, Toulouse, France

[13] Hosp Univ Vall DHebron, Med Oncol, Barcelona, Spain

[14] Mem Sloan Kettering Canc Ctr MSKCC, Med Oncol, New York, NY USA

[15] Gilead Sci Inc, Dept Clin Dev, Foster City, CA USA

[16] Gilead Sci Inc, Global Patient Safety, Foster City, CA USA

[17] Gilead Sci Inc, Clin Data Sci, Foster City, CA USA

[18] Harvard Med Sch, Dana Farber Canc Inst, Med Oncol, Boston, MA USA

来源：

ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期

关键词：

D O I：

10.1016/j.annonc.2022.08.012

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LBA76

引用

页码：S1386 / S1386

页数：1